The non-erythropoietic EPO fragment
The headline is that ARA-290 targets the innate repair receptor without the blood-building effect of full EPO. Studies look at how it binds that receptor and behaves in inflammation and nerve models. Mostly preclinical and early-clinical. None of it is a claim about what it does for a person.

